docetaxel injection solution
sandoz canada incorporated - docetaxel - solution - 10mg - docetaxel 10mg - antineoplastic agents
docetaxel injection solution
northstar rxllc - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel anhydrous 20 mg in 1 ml
docetaxel dakota
sanofi-aventis australia pty ltd - docetaxel -
docetaxel sanofi
sanofi-aventis australia pty ltd - docetaxel -
docetaxel winthrop
sanofi-aventis australia pty ltd - docetaxel -
docetaxel 20mg/ml concentrate for solution for infusion
seacross pharmaceuticals limited - docetaxel anhydrous - concentrate for solution for infusion - 20 milligram(s)/millilitre - taxanes; docetaxel
docetaxel 20mg/ml concentrate for solution for infusion
actavis group ptc ehf - docetaxel - concentrate for solution for infusion - 20 milligram(s)/millilitre - taxanes; docetaxel
docetaxel pfizer 10 mg/ml concentrate for solution for infusion
pfizer healthcare ireland - docetaxel - concentrate for solution for infusion - 10 milligram(s)/millilitre - taxanes; docetaxel
docetaxel mylan
mylan s.a.s. - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - antineoplastic agents - treatment of breast cancer, special forms of lung cancer (non-small-cell lung cancer), prostate cancer, gastric cancer, or head and neck cancer.
docetaxel-pf
viatris limited - docetaxel 40 mg/ml; - injection with diluent - 40 mg/ml - active: docetaxel 40 mg/ml excipient: citric acid nitrogen polysorbate 80 ethanol nitrogen water for injection - head and neck cancer docetaxel, in combination with cisplatin and fluorouracil is indicated in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.